INFORMATION
Vedolizumab is a recombinant protein that has the potential to induce humoral immune responses and lead to anti-drug antibody formation; a major cause of loss of response.
These Anti-drug antibodies can bind and neutralise the drug accelerating its clearance and reducing its efficacy. Monitoring the efficacy of Vedolizumab may help clinicians schedule a successful individualised treatment strategy for their patients.
Free Anti-Vedolizumab Antibody ELISA
Free anti-drug antibody ELISAs (“drug sensitive assays”) enable the detection of anti-drug antibodies that are not bound to other proteins or therapeutic drugs.
IDKmonitor® Vedolizumab Free Anti-drug Antibody ELISA is a quantitative assay that detects human antibodies against Vedolizumab in EDTA plasma and serum samples by capturing the anti-Vedolizumab antibodies on the microplate.
FEATURES
Detects free anti-Vedolizumab Antibodies in Serum and Plasma
Microplate coated with highly specific Vedolizumab fragments
1 calibrator, 2 controls
Capacity for 45 samples in duplicate
Assay time 130 minutes
Automatable on ELISA automates (e.g. Dynex D2)
BENEFITS
Supports the investigation of primary non response and loss of response to Vedolizumab
Drug sensitive assay only detects free anti-Vedolizumab antibodies (those not bound to Vedolizumab)
May help predict long term outcome of disease in patients with sub-therapeutic Vedolizumab levels
UK publications and evidence base
Available via reference laboratories in UK
Applicable to Gastroenterology
